{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:03:40Z","timestamp":1792598620370,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A11401"],"award-info":[{"award-number":["A11401"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["A27412"],"award-info":[{"award-number":["A27412"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["A22902"],"award-info":[{"award-number":["A22902"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["100282\/Z\/12\/Z"],"award-info":[{"award-number":["100282\/Z\/12\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["C1491\/A25351"],"award-info":[{"award-number":["C1491\/A25351"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["C1491\/A15955"],"award-info":[{"award-number":["C1491\/A15955"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xcrm.2024.101435","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T10:47:59Z","timestamp":1709030879000},"page":"101435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial"],"prefix":"10.1016","volume":"5","author":[{"given":"James","family":"Larkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-2167","authenticated-orcid":false,"given":"Nuria","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonzalez de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. Jeffry","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ottensmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valpione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-136X","authenticated-orcid":false,"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101435_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.xcrm.2024.101435_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/path.4204","article-title":"Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma","volume":"230","author":"Furney","year":"2013","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.xcrm.2024.101435_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/PPO.0b013e31824b2404","article-title":"Therapeutic implications of KIT in\u00a0melanoma","volume":"18","author":"Postow","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.xcrm.2024.101435_bib5","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1245\/s10434-016-5394-x","article-title":"Melanoma in Mexico: Clinicopathologic Features in a Population with Predominance of Acral Lentiginous Subtype","volume":"23","author":"Lino-Silva","year":"2016","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamadermatol.2016.0875","article-title":"Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma","volume":"152","author":"Marek","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.xcrm.2024.101435_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and Melanoma: Biological Insights and Clinical Implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.xcrm.2024.101435_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jaad.2019.01.081","article-title":"Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics","volume":"81","author":"Darmawan","year":"2019","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.xcrm.2024.101435_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1101\/gr.125591.111","article-title":"Whole genome sequencing of matched primary and metastatic acral melanomas","volume":"22","author":"Turajlic","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1755-148X.2012.01016.x","article-title":"Genomic characterisation of acral melanoma cell lines","volume":"25","author":"Furney","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101435_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.xcrm.2024.101435_bib13","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","article-title":"BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage","volume":"19","author":"Mar","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41591-018-0265-6","article-title":"Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma","volume":"25","author":"Trucco","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101435_bib15","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101435_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-020-20432-5","article-title":"Ultraviolet radiation drives mutations in a subset of mucosal melanomas","volume":"12","author":"Mundra","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101435_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J.\u00a0Carcinog."},{"key":"10.1016\/j.xcrm.2024.101435_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2017.07.029","article-title":"Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site","volume":"78","author":"Moon","year":"2018","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.xcrm.2024.101435_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246191","article-title":"Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis","volume":"20","author":"Ito","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101435_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/ajcp\/aqz209","article-title":"BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients","volume":"153","author":"Dika","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.xcrm.2024.101435_bib21","doi-asserted-by":"crossref","first-page":"40683","DOI":"10.18632\/oncotarget.16542","article-title":"Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations","volume":"8","author":"Cosgarea","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2024.101435_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CCO.0b013e32833888ee","article-title":"Mutation-driven drug development in melanoma","volume":"22","author":"Flaherty","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib23","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101435_bib24","article-title":"Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma","volume":"2018","author":"Mignard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","article-title":"Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)","volume":"119","author":"Nathan","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101435_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.602705","article-title":"Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review","volume":"10","author":"Zheng","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","article-title":"Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours","volume":"120","author":"Serrano","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4081\/rt.2010.e16","article-title":"Problems in rare tumor study: a call for papers","volume":"2","author":"Miller","year":"2010","journal-title":"Rare Tumors"},{"key":"10.1016\/j.xcrm.2024.101435_bib30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdu033","article-title":"Rare cancers: work in progress in Europe","volume":"25","author":"Casali","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib31","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101435_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12253-019-00788-w","article-title":"KIT Mutation Incidence and Pattern of Melanoma in Central Europe","volume":"26","author":"Doma","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib34","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/cncr.25766","article-title":"A phase 2 trial of dasatinib in advanced melanoma","volume":"117","author":"Kluger","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjc.6604482","article-title":"Phase II trial of imatinib mesylate in patients with metastatic melanoma","volume":"99","author":"Kim","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib36","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib37","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib38","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.29622","article-title":"Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma","volume":"121","author":"Buchbinder","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib39","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib40","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101435_bib41","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-14-1630","article-title":"Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition","volume":"21","author":"Carvajal","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib42","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib43","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1634\/theoncologist.2015-0161","article-title":"Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)","volume":"20","author":"Lee","year":"2015","journal-title":"Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib44","series-title":"MSc in Clinical Trials","article-title":"Advanced Melanoma Harbouring KIT Alterations: A Systematic Review of Targeted Therapy and What Conditions Result in a Greater Durable Response","author":"Parsons","year":"2018"},{"key":"10.1016\/j.xcrm.2024.101435_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib46","first-page":"210","article-title":"Immune-awakening revealed by peripheral T\u00a0cell dynamics after one cycle of immunotherapy","volume":"1","author":"Valpione","year":"2020","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xcrm.2024.101435_bib47","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/annonc\/mdw278","article-title":"Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA","volume":"27","author":"Gremel","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.21037\/tlcr-20-927","article-title":"Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients","volume":"10","author":"Fung","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","article-title":"Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments","volume":"34","author":"Ros","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib50","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib51","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/jid.2014.372","article-title":"KIT is a frequent target for epigenetic silencing in cutaneous melanoma","volume":"135","author":"Dahl","year":"2015","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.xcrm.2024.101435_bib52","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2013.50.4662","article-title":"Diagnosis and treatment of KIT-mutant metastatic melanoma","volume":"31","author":"Lyle","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101435_bib59","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101435_bib55","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101435_bib56","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101435_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/bioinformatics\/btr665","article-title":"SomaticSniper: identification of somatic point mutations in whole genome sequencing data","volume":"28","author":"Larson","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101435_bib61","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nmeth.1628","article-title":"CREST maps somatic structural variation in cancer genomes with base-pair resolution","volume":"8","author":"Wang","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101435_bib62","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib58","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2024.101435_bib60","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/bioinformatics\/btq330","article-title":"Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor","volume":"26","author":"McLaren","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101435_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","article-title":"Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients","volume":"88","author":"Valpione","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153901","article-title":"A Digital PCR-Based Method for Efficient and Highly Specific Screening of Genome Edited Cells","volume":"11","author":"Findlay","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101435_bib63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101435_bib64","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/sim.3123","article-title":"Proper inference from Simon's two-stage designs","volume":"27","author":"Koyama","year":"2008","journal-title":"Stat. Med."},{"key":"10.1016\/j.xcrm.2024.101435_bib65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/sim.1653","article-title":"On the estimation of the binomial probability in multistage clinical trials","volume":"23","author":"Jung","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.xcrm.2024.101435_bib66","first-page":"1","article-title":"OneArmPhaseTwoStudy: An R Package for Planning, Conducting, and Analysing Single-Arm Phase II Studies","volume":"81","author":"Kieser","year":"2017","journal-title":"J.\u00a0Stat. Software"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:17:07Z","timestamp":1778919427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2666379124000582"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101435","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101435"}}